Rivaroxaban or Aspirin for Biological Aortic Prosthesis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.

Also called NCT02974920

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02974920
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02974920. Randomized; no masking; primary purpose prevention. Start 2017-01-01 (actual); primary completion 2022-11-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rivaroxaban or Aspirin for Biological Aortic Prosthesis
Condition
Aortic Stenosis
Condition
Aortic Regurgitation
Condition
Thrombosis
Intervention (Drug)
Rivaroxaban 10 MG
Intervention (Drug)
Aspirin
Lead sponsor
Christian Torp-Pedersen (class: other)
Collaborator
Aalborg University Hospital (class: other)
Collaborator
Aarhus University Hospital (class: other)
Collaborator
Odense University Hospital (class: other)
Collaborator
Copenhagen University Hospital, Rigshospitalet (class: other)

Record details

Record id
cardio:ct-nct02974920
Content hash
08b4217ce20509f83f3b8c930976c3b3dd6e0c153d8d25a8c44edbad9b89b22a